Innovations in Rejection Surveillance after Heart Transplantation
For post-transplant management in heart patients, the endomyocardial biopsy is considered the gold standard to detect acute rejection. However, research has found that in biopsy assessments for rejection, concordance among expert pathologists is less than 67%. This presentation will explore case studies and the clinical use of novel technologies, including molecular diagnostic testing of intragraft mRNA transcripts and donor-derived cell-free DNA, for more accurate diagnosis of cellular and antibody-mediated rejection, acute rejection, and cardiac allograft vasculopathy (CAV).
Dr. Christopher Lawrence, Director, Medical Affairs | Thermo Fisher Scientific
Jon A. Kobashigawa MD | Director, Heart Transplant Program
Cedars-Sinai Medical Center, Los Angeles, California